XORTX Therapeutics (XRTX) Net Cash Flow (2022)

XORTX Therapeutics (XRTX) posted Net Cash Flow of -$9.6 million for Q4 2022, down 767.63% on a QoQ basis from $1.4 million in Q3 2022.

XORTX Therapeutics (XRTX) Net Cash Flow (2022) Analysis & Trends

XORTX Therapeutics' Net Cash Flow history runs 1 years deep, the most recent figure standing at -$9.6 million for Q4 2022.

Quarterly Net Cash Flow changed N/A year-over-year to -$9.6 million in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$9.6 million (down 767.63% YoY) and the FY2025 annual result came in at -$1.6 million, down 74.42% from the prior year.
Net Cash Flow was -$9.6 million for Q4 2022 at XORTX Therapeutics, down from $1.4 million in the prior quarter.
Across five years, Net Cash Flow topped out at $1.4 million in Q3 2022 and bottomed at -$9.6 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	10.56 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	224.46 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.34 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	457.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-152.20 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	57.19 Mn
10	XORTX Therapeutics	20.40 Mn	20.40 Mn	-	-

Download Data